Merck Went Own Way On Bezlotoxumab Endpoint And FDA May Not Follow
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck rejected FDA's recommended endpoint to show efficacy in preventing C. difficile recurrence, which could make it difficult to gain approval for the product, headed to June 9 advisory panel review.
You may also be interested in...
Merck’s C. Diff Drug Zinplava Clears FDA With Heart Failure Warning
Following panel recommendation, label includes warning of use of bezlotoxumab in patients with history of congestive heart failure; postmarketing commitments include studies on microbial retention and endotoxin recovery.
Merck’s Bezlotoxumab C. Difficile Data Pave Way For Antibodies
Company readies regulatory filings for bezlotoxumab as a monotherapy in preventing C. difficile, following presentation of positive MODIFY I and II data at the ICAAC meeting in San Diego.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.